Expression of liver cancer associated gene HCCA3

Zheng-Xu Wang¹, Gui-Fang Hu¹, Hong-Yang Wang², Meng-Chao Wu²

¹Department of General Surgery, Chinese PLA General Hospital of Lanzhou Military Command, Lanzhou 730050, Gansu Province, China
²Eastern Hepatobilliary Surgical Hospital, Second Military Medical University, Shanghai 200438, China

Supported by the National Natural Science Foundation of China No. 30000077, and Science Funds for Post-doctoral Studies (1999[10]), and Medical and Health Project Funds of Chinese PLA Lanzhou Command (LXH01-01)

Correspondence to: Dr. Zheng-Xu Wang, Department of General Surgery, Chinese PLA General Hospital of Lanzhou Military Command, No. 98, Xiaoxihu West Street, Block Qilihe, Lanzhou 730050, Gansu Province, China. zhxwang18@hotmail.com

Abstract

AIM: To study and clone a novel liver cancer related gene, and to explore the molecular basis of liver cancer genesis.

METHODS: Using mRNA differential display polymerase chain reaction (DDPCR), we investigated the difference of mRNA in human hepatocellular carcinoma (HCC) and paired surrounding liver tissues, and got a gene probe. By screening a human placenta cDNA library and genomic homologous extend, we obtained a full-length cDNA named HCCA3. We analyzed the expression of this novel gene in 42 pairs of HCC and the surrounding liver tissues, and distribution in human normal tissues by means of Northern blot assay.

RESULTS: A full-length cDNA of liver cancer associated gene HCCA3 has been submitted to the GeneBank nucleotide sequence databases (Accession No. AF276707). The positive expression rate of this gene was 78.6% (33/42) in HCC tissues, and the clinical pathological data showed that the HCCA3 was closely associated with the invasion of tumor capsule (P = 0.023) and adjacent small metastasis satellite nodules lesions (P = 0.041). The HCCA3 was widely distributed in the human normal tissues, which was intensively expressed in lungs, brain and colon tissues, while lowly expressed in the liver tissues.

CONCLUSION: A novel full-length cDNA was cloned and differentiated, which was highly expressed in liver cancer tissues. The high expression was closely related to the tumor invasiveness and metastasis, that may be the late hereditary change in HCC genesis.

Subject headings Carcinoma, hepatocellular/genetics; DNA, Complementary/genetics; Liver neoplasms/genetics; RNA, messenger/genetics; Gene expression; Polymerase chain reaction

INTRODUCTION

Primary hepatocellular carcinoma (HCC) is one of the most common fatal malignant tumors in China¹-²⁰. According to the statistics of our country, primary liver cancer claims 20.40 lives per 100 000 people annually, with 19.98 per 100 000 in cities and 23.59 per 100 000 in rural areas, ranking as the 2nd and the 1st leading cause of cancer death, respectively. Of all the newly enrolled cases in the world each year, 45% are found in the mainland of China. In the southeast areas of high incidence, the situation is even worse with tumors tending to occur in a younger age group. The molecular events for HCC development are very complex, and HCC has proved to be genetically heterogenous neoplasms²¹-³⁰. But to date, the identified genes have not yet fully disclosed the mechanisms of HCC³¹-³⁸. In an attempt to identify HCC susceptible genes, differential display method was employed in this study. In the analysis of altered expression genes between HCC tissues and their nontumor counterparts, we isolated a novel gene named HCCA3 with a full length of cDNA.

MATERIALS AND METHODS

Materials

PCR polymerase is a product of Promega (Madison, USA); isotope α-32P-dATP was purchased from Amersham Pharmacia Biotech (Arlington Heights, IL); Qiaex II gel extraction kit were from Qiagen (Hilden, Germany); pGEM-T vector were from Promega; human placental cDNA library were from Clontech (USA); nitrocellulose were from Amersham Pharmacia Biotech; Prime-a-Gene Labeling System were from Promega; 14-mer anchored oligo (dT) primer (dT₁₂ CA) and an arbitrary 10-base oligonucleotide A2 (5'-ATCGGGCTG-3') were donated by Professor Pei.

Patients and specimens

Primary HCC and their surrounding liver tissues were obtained from 42 patients who received surgical resection at the Eastern Hepatobiliary Surgical Hospital of the Second Military Medical University, Shanghai, China. These included 41 male and 1 female patients with a median age of 49 years (range 24-72 years, mean age of 49.8 years). Thirty-five (83.3%) patients had serological evidence of hepatitis B virus infection. The serum AFP level was above 25 µg·L⁻¹ in 23 cases (54.8%). The tumor size was smaller than 5 cm (small HCC) in 13 patients and larger than 5 cm in 29. Histologically, 40 patients (95.2%) were complicated with cirrhosis. There were 7 well differentiated (Edmondson’s grades I and II) and 35 poorly differentiated (Edmondson’s grades III and IV) HCCs. Macroscopic portal vein tumor spread was found in 3 patients, and microscopic surrounding liver vascular cancer thrombi were found in 26. Gross and microscopic intrahepatic adjacent small satellite nodules lesions were found in 28, and tumor capsule invasion of liver cancer in 32. Adult normal tissues were obtained from a healthy young man who died of a traffic accident.

Methods

RNA extraction and differential display Total cytoplasmatic RNA was extracted by the acid guanidinium thiocyanate-phenol - chloroform extraction method⁴⁹-⁵⁰. The differential display method
was performed as described previously[39,41,42]. Amplification consisted of initial denaturation at 94°C for 4 min, followed by 40 reaction cycles (60 s at 93°C, 2 min at 40°C, and 90 s at 70°C) and a final cycle at 72°C for 10 min. PCR fragments were then reamplified by the same primer, separated on a 16 % agarose gel, purified by QiAex II gel extraction kit, and subcloned into the pGEM-T vector using standard molecular cloning techniques.

**Library screening and DNA sequencing** Fragment contained in the PCR clone (length in 350 base pairs) from DDPCR served as probe to screen placental cDNA library, using the standard filter hybridization techniques described[43,44]. At the end of the third screening, we got several plagues containing the target DNA sequence and sequenced them by DNA automated sequencing system. To obtain the cDNA in a full length, genomic homologous screening was used through comparing the cDNA sequence obtained by screening the library with the NCBI GeneBank EST database. We used the PCR assay and sequencing to confirm the correct ness of the cDNA sequence.

**Northern blot assay** For Northern blot analysis[37,40,44], 40 µg of total RNA was denatured, loaded on a 15 % agarose gel and ran at 5 V·cm⁻¹ for about 3 h. The collected gels were then transferred to nitrocellulose. Hybridization of the filters was performed using specific probe of HCCA3 cDNA fragment (length in 1125 bp) obtained from screening the library. The probe was labeled with 50 µCi A-32P-dATP using Prime-a-Gene labeling kit according to the given protocol. After prehybridization at 42°C for 3 h, the membranes were hybridized in the same solution containing the labeled probe for 6 h at the same temperature, and exposed to X-ray film for 10 d at-70°C. In order to calibrate relative quantities of loaded RNAs, the blot was rehybridized with a cDNA probe of the ß-Actin gene.

**Statistical analysis** χ² test or Fisher’s exact test was used to examine the differences and relationship among groups of patients classified by HCCA3 expression. Differences at P<0.05 were judged to be statistically significant.

**RESULTS**

**Differential display analysis and library screening** By DDPCR, we found a differentially expressed gene fragment that exclusively present in the liver cancer lane. This fragment (length in 350 bp) was then subcloned into pGEM-T vector and served as specific probe to screen human placental cDNA library. We have obtained the gene fragment of 1125 bp in length, which shortened nearly 600 bp according to the location of Northern hybridization by screening the library. We also obtained the full-length cDNA of 1706 bp, which was in good agreement with the size of the mRNA species observed by Northern blotting through genomic homologous extend, along with the EST sequence (GeneBank Accession No. AP001077, length in 197663 bp) of NCBI GeneBank EST databases. The sequence of 1706 bp in length was corrected by PCR assay and sequencing. It was named HCCA3 (HCC associated gene 3, also named STW-2) and submitted to EMBL/GenBank/DDBJ nucleotide sequence databases (Accession No. AF27 6707).

**Sequence characteristics of the full-length HCCA3**

HCCA3 contains a consensus initiation codon[39,40] at position 681 followed by a single open reading frame of 792 bp encoding 264 amino acids. The 3’ untranslated region of 230 bp had a consensus polyadenylation signal (AATAAA) beginning 16 bases upstream the poly (A) tail. Alignment at nucleotide and amino acid level showed no significant homologues with known genes. The deduced protein was estimated to be 29 396 dalton and has a pI of 6.93. Amino acid sequence analysis by GCG sequence analysis software package (version 9.1, Genetics Computer Group, Madison, Wisconsin) and PC/GENE (Version 5.03, Geneva University, Switzerland) showed that there were several putative modification sites. These include two N-glycosylation sites at amino acid of 40 and 67, three N-myristoylation sites at amino acid of 183, 185 and 258, five phosphorylation sites for protein kinase: two protein kinase C (PKC) phosphorylation sites at 82 and 250, three cases in kinase II phosphorylation sites at 8, 189 and 209. No transmembrane domain and signal peptide was found. Further more, there was no nuclear targeting sequence. The schematic presentation of HCCA3 cDNA is shown in Figure 1.

**Normal tissue distribution of HCCA3 Mrna**

Northern blot analysis showed that HCCA3 mRNA appears to be widely expressed in human normal tissues (Figure 2). The HCCA3 gene was particularly highly expressed in human lungs, brain and colon, moderately expressed in muscle, stomach, spleen and heart tissues, weakly expressed in small intestines, pancreas, and liver tissues. Among the tissues with positive signals, HCCA3 mRNA was observed in a transcript of approximately 1.7 kb which well corresponded to the size of the cloned cDNA.

**Figure 2**  Northern blot analysis of HCCA3 mRNA in human adult normal tissues. Upper panel showed HCCA3 mRNA was highly expressed in human lungs, brain and colon, moderately expressed in muscle, stomach, spleen and heart tissues, weakly expressed in small intestines, pancreas, and liver tissues. Equal amounts of total RNA loading as indicated by 28S and 18S rRNAs were used for evaluating the quality and quantity of RNA loading (lower panel).

**Figure 3**  Differential expression of HCCA3 analyzed by Northern blot. Upper panel shows that HCCA3 mRNA was highly expressed in HCC tissues (H), and lowly in paired surrounding liver tissues (L). A signal transcript of 1.7 kb is shown in six tumors. 28S and 18S rRNAs were used for evaluating the quality and quantity of RNA loading (lower panel).
**HCCA3 mRNA expression in HCC and its clinical significance**

HCCA3 mRNA expression was noticed in 78.6% (33/42) patients, which was intensively expressed in HCC tissues (Figure 3), while lowly expressed in the surrounding liver tissues. To investigate the potential biological role of HCCA3 in the development of HCC, we further investigated its expression in HCC with extensive samples and compared with the clinically pathological parameters. The mRNA expression level of HCCA3 was associated with the invasion of liver cancer capsule and the adjacent small satellite nodules lesions ($P<0.05$), but not with tumor size, tumor differentiation, serum AFP, hepatitis B virus (HBV) infection and microscopic vascular cancer cell thrombi ($P>0.05$). The results are listed in Table 1.

![Image](image_url)
**DISCUSSION**

Differential display polymerase chain reaction (DDPCR) method is a useful tool for detecting and characterizing altered gene expression in eukaryotic cells. Using this technique, we have successfully isolated a gene named HCCA3 with a transcript of 1706 bp. A consensus initiation codon is at 681 bp and the fr anxious sequence of the predicted initiating me thionine coincides with Kozak criterion because the nucleot ides at -3, +4 site of start codon are purine, and there is one stop codon at the upstream sequence. The length of HCCA3 cDNA agrees with the size of mRNA by Northern blot analysis. No significant homologues with known genes at nucleotide and amino acid levels were found. No signal peptides searched by GCG and PC/GENE software were found, suggesting that HCCA3 was not a secretory protein. This protein also has no transmembrane domain and nuclear targeting sequence indicating that it may not be located on cell membrane or within nucleus. The putative protein of HCCA3 revealed several phosphorylation sites for protein kinase C and casein kinase II. However, it is generally accepted that protein phosphorylation-dephosphorylation plays a role in the regulation of essentially all cellular functions, and there is evidence that deregulation of protein phosphorylation is involved in several human cancers. As a possible oncoprotein, it may be functionally abnormal, and phosphorylation deregulation may be a mechanism. The function of HCCA3 protein may also largely depend on its phosphorylation status. However, this needs further studies.

Studies on the expression of HCCA3 can reveal its potential biological significance. By Northern blot analysis, we noted that HCCA3 mRNA was expressed widely in normal human tissues, indicating that HCCA3 is a normal cellular gene which may be involved in the physical process of the distributed tissues. Although HCCA3 mRNA was expressed in normal liver tissues, it was significantly expressed in HCC tissues, suggesting that HCCA3 is a very common molecular event involved in the pathogenesis of HCC. The 1479-1486

**REFERENCES**

1. Tang ZY. Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol, 2001; 7:445-454
2. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, Wu ZQ, Fan J, Qin LX, Zheng BH. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer, 2001; 91:1479-1486
3. Wu M. Clinical advances in primary liver cancer in China. Hepatogastroenterology, 2001; 48:29-32
4. Wang ZX, He ZP, Wu ZZ, Zhang WW. Induction of apoptosis in human hepatocellular carcinoma cells by adenoviral-mediated transfer of human multigene. Zhonghua Ganzhangbing Za Zhi, 2000; 8:224-226
5. Jiang YF, Yang ZH, Hu QJ. Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol, 2000; 6:61-65
6. Ma XD, Sun YF, Wang WL. Expression of gap junction genes connexin 32, con nexin 43 and their proteins in hepatocellular carcinoma and normal liver tissues. World J Gastroenterol, 2000; 6:66-69
7. Kong XB, Yang ZK, Liang LJ, Huang JF, Li HL. Overexpression of Pglycoprotein in hepatocellular carcinoma and its clinical implication. World J Gastroenterol, 2000; 6:134-135
8. Sun BH, Zhao XP, Wang BJ, Yang DL, Hao LJ. FADD and TRADD expression and apoptosis in primary human hepatocellular carcinoma. World J Gastroenterol, 2000; 6:244-248
9. Yang DH, Zhang MQ, Du J, Liang QM, Mao JF, Qin HR, Fan ZR. Inhibitory effect of GF-II antisense RNA on malignant phenotype of hepatocellular carcinoma. World J Gastroenterol, 2000; 6:266-267
10. Sithinamsuwann P, Piratvisuth T, Tanomkit K, Apakupakul K, Tongyoo S. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital. World J Gastroenterol, 2000; 6:339-343
11. Sun BH, Zhang J, Wang BJ, Zhao XP, Wang YK, Yu QZ, Yang DL, Hao LJ. Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p53 WAF1 expression and hepatic apoptosis. World J Gastroenterol, 2000; 6:356-360
12. Wang Y, Liu H, Zhou Q, Li X. Analysis of point mutation in site 1896 of HBV precore and its detection in the tissues and serum of HCC patients. World J Gastroenterol, 2000; 6:395-397
13. Zhu HZ, Ruan YB, Wu ZB, Zhang CM. Kupffer cell and apoptosis in experimental HCC. World J Gastroenterol, 2000; 6:405-407
14. Mei MH, Xu J, Shi QF, Yang JH, Chen Q, Qin L. Clinical significance of serum intercellular adhesion molecule-1 detection in patients with hepatocellular carcinoma. World J Gastroenterol, 2000; 6:408-410
15. Qin Y, Li B, Tan YS, Sun ZL, Zuo FQ, Sun ZF. Polymorphism of p16/INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma. World J Gastroenterol, 2000; 6:411-414
16. Shen LJ, Zhang ZJ, Ou YM, Zhang HX, Huang R, He Y, Wang MJ, Xu GS. Computed morphometric analysis and expression of alpha-fetoprotein in hepatocellular carcinoma and its related lesion. World J Gastroenterol, 2000; 6:415-416

---

**Table 1: Relationship between HCCA3 mRNA expression and clinicopathological features in HCC**

| Clinicopathology | n | Positive n (%) |
|------------------|---|----------------|
| Tumor size (cm)  |   |                |
| <5               | 10| 6 (60.0)       |
| >5               | 32| 27 (84.4)      |
| Tumor differentiation | |                |
| Well            | 7 | 4 (57.1)       |
| Poor            | 35| 29 (82.9)      |
| Serum AFP (µg/L) |   |                |
| <25             | >19| 15 (79.0)    |
| >25             | 23| 18 (78.3)      |
| HBV infection   |   |                |
| Positive        | 35| 28 (80.0)      |
| Negative        | 7 | 5 (71.4)       |
| Capsule invasion|   |                |
| Positive        | 32| 28 (87.5)      |
| Negative        | 10| 5 (50.0)*      |
| Cancer thrombi  |   |                |
| Positive        | 26| 21 (76.9)      |
| Negative        | 16| 12 (82.4)      |
| Satellite lesions| |                |
| Positive        | 28| 25 (89.3)      |
| Negative        | 14| 8 (57.1)*      |

*P<0.05, vs positive.
36 Martins C, Kedda MA and Kew MC. Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. World J Gastroenterol 1999; 5: 470-474

37 Zhong J, Jiang H, Wu Q, Peskta S, Fisher PB. Cloning and characterization of human ubiquitin-processing protease that is inducible by polyamine analogue exposure. Cancer Res, 2001; 61: 5370-5373

38 Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe H, Gozani O, Horita K. Identification of a novel gene in the TOC region on 17q25.1 that shows loss of expression in multiple human cancers. J Hum Genet, 2001; 46: 90-95

39 Droese M. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepato cellular carcinoma and focal nodular hyperplasia. Br J Cancer, 1999; 80: 73-78

40 Wang L, Lu W, Chen YZ, Zhou HM and Gu JR. Comparison of gene expression between normal colon mucosa and colon carcinoma by means of messenger RNA differential display. World J Gastroenterol, 1999; 5: 533-534

41 Takcels-Horde D, David M, Williams AJ, Wilson DJ, Eskandari T, Vogt LM, Boland JF, Scherf U, Vogt K. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer, 2001; 92: 395-405

42 Zhao J, Mei MH, Zeng SE, Shi QF, Liu YM, Qin LL. Expressions of c-myc, c-erbB-2 and p53 in primary liver cancer. J Cancer Res, 2001; 20: 2704-2712

43 Yamashita T, Kaneko S, Hashimoto S, Sato T, Nagai S, Toyoda N, Suzuki T, Kobayashi K. Expression of p21WAF1/CIP1 in hepatocellular carcinoma using suppression subtractive hybridization. World J Gastroenterol, 2001; 7: 28-32

44 Wang HY, Fuchs M, Ciosekk T, Chen ZJ and Ulrich A. Mammary Subfamily Protein T yrosine Phosphatases during Mouse Development. Mech Dev, 1998; 70: 91-109

45 Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, Ji Y, Wu X, Han Z, Hu G. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res, 2001; 61: 3176-3181

46 Hazuda H, Nagai H, Tsunemizu M, Mikami I, Sugano S, Emi M. Identification of DMCI, a novel gene in the TOC region on 17q25.1 that shows loss of expression in multiple human cancers. J Hum Genet, 2001; 46: 90-95

47 Robb CW, Oishiuela CJ, Ekkelenkamp MB, Niewel DW. Identification and characterization of an in vivo regulated D15/Oma87 homologue in Shigella flexneri using differential display polymerase chain reaction. Gene, 2001; 262: 169-177

48 Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NFR family of transcription factors that is coordinately up-regulated with growth suppressing properties in lung cancer. Cancer Res, 1999; 59: 35-43

49 Wang Y, Devereux W, Woster PM, Stewart TM, Hacker A, Casero RA Jr. Cloning and characterization of a human polyanine oxidase that is inducible by polyamine analogue exposure. Cancer Res, 2001; 61: 3970-3973

50 Kang D, Jiang H, Wu Q, Peskta S, Fisher PB. Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH. Biochem Biophys Res Commun, 2001; 282: 647-654

51 Miyata M, Yamamoto M. Identification and characterization of genes associated with cDNA microarrays. Gene, 2001; 267: 233-242

52 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

53 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

54 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

55 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

56 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

57 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

58 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

59 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

60 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242

61 Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with suppression subtractive hybridization. Semin Liver Dis, 2001; 21: 235-242